The GLP-1 weight loss drugs revolutionizing the treatment of obesity, diabetes and a slew of other diseases come with a major caveat: They don’t work for everyone. Some people experience profound ...

AUGUSTA, Ga. — One boy was white, and soon after World War II his father became the proprietor of the Augusta Municipal Golf Course. There was inherent middle-class status to the job, as the son came ...

Our expert staff answers frequently asked questions in their areas of expertise and defines common terms so you can be a smarter shopper. Read more here. Over the past few years, nano-hydroxyapetite ...

NASA astronauts design mission patches to tell the story of each shuttle mission, a tradition dating back to the 1960s. The mission patch for the Artemis II mission was revealed in 2025, with a ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

A couple of decades ago, GLP-1 drugs were a specialised treatment for type-2 diabetes but, fast-forward to today, and they have become much more widespread, being sold to help people with obesity and ...

The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies. The orforglipron pill, called ...

The FDA approved a new GLP-1 pill called Foundayo (orforglipron) for adults with obesity or who are overweight and have weight-related health issues. Unlike the Wegovy pill, Foundayo has no food or ...

A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial ...

Recent research has highlighted the role of neuroinflammation and vascular dysfunction in Alzheimer’s disease (AD). Semaglutide, a GLP-1 receptor agonist, has shown promise in reducing inflammation ...